Global Estimate of Clarithromycin Resistance in Clinical Isolates of Helicobacter pylori: a Systematic Review and Meta-Analysis

Background: A high resistance rate to clarithromycin usually leads to failure to eradicate Helicobacter pylori. The aim of the present study was to review recent data on H. pylori resistance towards clarithromycin in clinical studies worldwide. Methods: PubMed/Medline, Web of Science, and Embase were used for a systematic review from 1 January 2011 to 13 April 2021 to retrieve the clinical trial studies. Data were analyzed according to publication year, age, geo-graphic area, and minimum inhibitory concentration (MIC). Statistical analysis was done by STATA version 14.0 (College Station, Texas). Results: From a total of 4,304 articles, 89 articles related to clinical studies were selected for analysis. The overall H. pylori clarithromycin resistance rate was 34.95. Based on continents, the highest and lowest pooled estimate of the bacterial resistance rates were observed in Asia (35.97) and North America (7.02), respectively. The highest and the lowest pooled estimate of H. pylori resistance rate to clarithromycin based on country were ob-tained in Australia (93.4) and USA (7), respectively. Conclusions: H. pylori resistance to clarithromycin in most parts of the world is more than 15, so it is recom-mended that each country, after estimating the rate of resistance to clarithromycin, determine the treatment/erad-ication pattern for H. pylori infection. © 2023 Verlag Klinisches Labor GmbH. All rights reserved